替比夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的临床观察

目的评价替比夫定治疗HBeAg阳性慢性乙型肝炎48周的疗效和安全性。方法将HBeAg阳性慢性乙型肝炎患者104例分为两组,治疗组53例,对照组51例。治疗组口服替比夫定600mg,每日1次,疗程48周;对照组口服阿德福韦酯10mg,每日1次,疗程48周。观察两组治疗12、24、36、48周时的HBV-DNA阴转率、ALT复常率、HBeAg阴转率、HBeAg血清转换率及治疗过程中的不良反应。结果治疗12、24、36、48周时,两组HBV-DNA阴转率、ALT复常率相比较差异有统计学意义(P﹤0.05),而HBeAg阴转率及HBeAg血清转换率相比较差异无统计学意义(P﹥0.05)。治疗组在服药期间未出现严重不良反应。结论替比夫定治疗HBeAg阳性慢性乙型肝炎是有效的和安全的。

Clinical observation on telbivudine and adefovir dipivoxil in the treatment of HBeAg positive chronic hepatitis B

OBJECTIVE To evaluate the efficacy and safety of 48 weeks telbivudine(LdT)treatment for chronic hepatitis B patients with HBeAg positive.METHODS 104 chronic hepatitis B patients with HBeAg positive were divided into treatment group(53 cases)and control group(51 cases).The treatment group was treated with telbivudine 600 mg per day orally for 48 weeks,the control group was treated with adefovir dipivoxil 10 mg per day orally for 48 weeks.The patients in both groups were observed of the rates of serum HBV-DNA clearance,ALT normalization,HBeAg loss,HBeAg seroconversion and side effects during the following 12,24,36 and 48 weeks.RESULTS After treatment of 12 weeks,24 weeks,36 weeks and 48 weeks,there were significant differences in the rates of serum HBV-DNA clearance and ALT normalization between the two groups(P﹤0.05),and there were no significant differences in the rates of HBeAg loss and HBeAg seroconversion(P﹥0.05).No severe adverse reactions were found in the treatment group.CONCLUSION Telbivudine is effective and safe in the treatment of chronic hepatitis B with HBeAg positive.